BMS Reports Sub-Study Results of the P-III Trial (CheckMate -901) for Opdivo (nivolumab) to Treat Unresectable or Metastatic Urothelial Carcinoma
Shots:
- The company highlighted the sub-study results of the P-III trial evaluating Opdivo + Yervoy (primary study) or Opdivo + CT (sub-study) vs CT alone in 608 patients with untreated unresectable or metastatic urothelial cancer
- The study met the dual 1EPs of OS & PFS as assessed by BICR at the final analysis, Opdivo + cisplatin-based CT showed a significant benefit in OS & PFS and had a tolerable safety profile consistent with the known safety profiles of the individual components of the regimen with no new safety concerns
- The company will discuss the results with health authorities while the study of Opdivo + Yervoy remains ongoing for patients with untreated, unresectable, or metastatic urothelial carcinoma
Ref: Businesswire | Image: BMS
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
